Johnson & Johnson: Valuation Premium Justified (NYSE:JNJ)

Johnson & Johnson’s ( JNJ ) revenue and earnings growth are poised to accelerate moving forward. The company's growth should benefit from the ramp-up of TREMFYA, which is successfully replacing STELARA after loss ofI have over 15 years of experience investing and have provided research services to mid-sized hedge funds with assets under management between $100 and $500 million. I also have had a brief stint as a sell-side analyst. I am now focusing primarily on managing my own money and my purpose here is t ...